Welcome to AirSculpt Technologies Incorporated fourth-quarter 2024 earnings call. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce Allison ...
SAN DIEGO -- Two retrospective studies hinted at potential negative effects of GLP-1 receptor agonists for patients requiring ...
Tirzepatide and semaglutide were associated with larger QALY gains (incremental gains of 0.35 and 0.25 over lifestyle ...
Depression risk for patients receiving GLP-1 RA was slightly higher than those receiving SGLT-2i and lower than those receiving DPP-4i.
Patients who continued Ozempic through total joint arthroplasty had higher risk for complications compared with those who stopped GLP-1RAs before surgery.
Consolidated revenues increased 43% year-over-year to $64.3 million with telehealth revenue up 60%Adjusted EBITDA increased 78% to $9.0 millionTelehealth adjusted EBITDA increased 396% to $5.9 million ...
PMGC Holdings Inc. (NASDAQ: ELAB) ("PMGC" or the "Company") today announced that it will effect a 1-for-7 reverse stock split (the "Split") of ...
Forbes contributors publish independent expert analyses and insights. Hugh McIntyre covers music, with a focus on the global charts.
The above chart underscores the current buzz that ... And those gains followed a return of 31.5% in 2024, on the success of the company's GLP-1 medications for Type 2 diabetes and weight loss.
Here's why I think it can be the best GLP-1 stock to buy this year. Amgen's weight loss drug only needs to be taken once a month The top GLP-1 treatments on the market today require weekly injections.
I expect price sensitive consumers to flood the market for compounded GLP-1 drugs before the 60-day FDA grace period for semaglutide compounders. HIMS projects $725M in GLP-1 weight loss revenue ...
Whether you’ve just started taking semaglutide for weight loss or are considering other GLP-1 medications ... The long answer along with a dosage chart you can find below.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results